Short Communication Open Access
Volume 3 | Issue 1 | DOI: https://doi.org/10.33696/pathology.3.033
Can Artificial Intelligence Help?
Nguyen Thanh Duc1, Jae Hyun Park2, Kyudong Han3, Boreom Lee4, Yong-Moon Lee5,*
- 1Department of Neurology and Neurosurgery, Montreal Neurological Institute, McGill Univ, Montreal, Canada
- 2Department of Surgery, Wonju Severance Christian Hospital, Yonsei University, Wonju College of Medicine, South Korea
- 3Center for Bio-Medical Engineering Core Facility, Dankook University, Cheonan, South Korea
- 4Department of Biomedical Science and Engineering (BMSE), Gwangju Institute of Science and Technology (GIST), Gwangju, South Korea
- 5Department of Pathology, College of Medicine, Dankook University, Cheonan, South Korea
Corresponding Author
Yong-Moon Lee, vilimoon@daum.net
Received Date: January 27, 2022
Accepted Date: April 07, 2022
Nguyen TD, Park JH, Han K, Lee B, Lee Y-M. Can Artificial Intelligence Help!. J Exp Pathol. 2022;3(1):12-15.
Copyright: © 2022 Nguyen TD, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Recommended Articles
DILI, HILI, RUCAM Algorithm, and AI, the Artificial Intelligence: Provocative issues, Progress, and Proposals
Artificial Intelligence (AI) principles published in 1956 included the recommendation to use algorithms for solving complex processes. The creation of the Roussel Uclaf Causality Assessment Method (RUCAM) was published in 1993 with integration of an intelligent algorithm to solve issues of causality assessment in cases of complex suspected drug induced liver injury (DILI) cases. Other causality assessment methods (CAMs) published before the era of AI and RUCAM followed rather general principles without precise and valid algorithm.
Artificial Intelligence and Machine Learning in Cancer Care: Current Applications and Future Perspectives
Cancer is the second most common cause of death worldwide, accounting for an estimated 9.6 million deaths in the year 2018, a number that is expected to grow to more than 13 million by 2030. In the past decade, we have witnessed unprecedented scientific advancement in the understanding of cancer etiology, prevention, diagnosis and development of new therapeutic strategies.
Artificial Intelligence in Pharma: Positive Trends but More Investment Needed to Drive a Transformation
Pharmaceutical companies have been actively adopting artificial intelligence (AI) approaches for drug discovery and are starting to focus this technology on clinical trials. The shift from large-scale collaborations to smaller strategic partnerships and recently to internal teams has led to increased headcounts that are being organized to deliver AI across the enterprise. Although the urgency of the COVID-19 could have been a perfect test case for leveraging AI, it drew awareness to the obstacles of data access.
Comparing Contrast Agent Enhancement: The Value of Artificial Intelligence/Machine Learning
Gadolinium-based contrast agents (GBCAs) work by shortening the T1, T2, and T2* relaxation time constants of adjacent water protons in tissues.
Can Artificial Intelligence Help?
Papillary thyroid carcinoma (PTC) is the fifth most common malignant tumor in women worldwide and the most common cancer in women younger than 25 years [1]. Fortunately, the first is that the prognosis is excellent compared to other malignant tumors [2].